Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Biolingus · Diabete Type 2
Phase 1 / Phase 2
Recruiting
15
2025-02
Industry sponsor intelligence
BiolingusClinical Pipeline.
Lead-sponsor view of Biolingus's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 15
Pipeline overview
Programs by phase and activity.
Velocity
Biolingus trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Liraglutide → | 1 | 1 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Biolingus studies.
This page groups studies where Biolingus is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates